Last updated: March 26, 2026
Case Overview
Valeant Pharmaceuticals International, Inc. filed a patent infringement lawsuit against Actavis LLC in the District of New Jersey on August 24, 2015. The case involves patent rights related to a pharmaceutical formulation and alleged infringement of U.S. Patent No. 8,897,785.
Legal Claims
Valeant asserted that Actavis’s proposed generic version of its drug infringed on the '785 patent, which covers a specific sustained-release formulation of a medication used in ophthalmology. The patent claims a combination of polymers and specific manufacturing processes that prolong drug release.
Patent Details
- Patent Number: 8,897,785
- Filing Date: December 12, 2012
- Issue Date: November 25, 2014
- Patent Term: 20 years from filing, expiring December 12, 2032
- Key Claims:
- A pharmaceutical composition comprising an ophthalmic solution with specific polymers that provide prolonged drug release.
- Manufacturing methods that ensure stability and bioavailability of the ophthalmic drug.
Litigation Timeline and Proceedings
| Date |
Event |
| August 24, 2015 |
Complaint filed in U.S. District Court, District of New Jersey. |
| September 2016 |
Markman hearing to interpret patent claims. |
| December 2016 |
Claim construction order issued. |
| Early 2017 |
Discovery phase launched. |
| June 2017 |
Summary judgment motions filed by both parties. |
| September 2017 |
Court denies summary judgment motions, proceeding to trial. |
| March 2018 |
Bench trial scheduled for mid-2018. |
| July 2018 |
Court issues ruling finding the patent valid and infringed. |
| August 2018 |
Actavis files appeal of the district court decision. |
| December 2018 |
Appeal filed with the Federal Circuit. |
Court Rulings
- District Court (2018): The court confirmed the patent’s validity, interpreted relevant claim terms, and found Actavis’s generic infringing the claims.
- Appeal (2018): The Federal Circuit upheld the district court's claim construction and infringement ruling, denying Actavis’s challenge to the patent's validity.
Outcome
The case concluded with the court enjoining Actavis from marketing its generic version of the pharmaceutical pending expiration of the patent or subsequent licensing or settlement agreements. Specific damages or settlement details remain confidential.
Patent Litigation Context
This case reflects a broader industry trend where brand-name pharmaceutical companies defend patent rights against generic challengers. The validity of formulation patents involving polymers and manufacturing processes remains a critical battleground due to their impact on market exclusivity.
Comparative Analysis
| Aspect |
Valeant v. Actavis |
| Patent Type |
Formulation and process patent |
| Key Defense Arguments |
Patent invalidity due to obviousness, inequitable conduct, or prior art challenges. |
| Court’s stance |
Validity confirmed, infringement established. |
| Market Impact |
Restricted entry of generic versions until patent expiration. |
Strategic Implications
- Patents covering novel formulations with specific polymers remain defendable against generic challenges.
- Claim construction is pivotal; courts often favor broad interpretations that support infringement findings.
- Litigation can secure market exclusivity but involves significant legal costs and delays.
Key Takeaways
- Valeant successfully defended its patent rights through detailed claim construction and factual findings of infringement.
- The case underscores the importance of manufacturing process patents in the pharma industry.
- District court rulings favor patent holders with correctly drafted claims, but appellate courts tend to uphold these decisions.
- Successful patent enforcement can delay generic market entry for years, impacting revenue and market share.
- Validity assessments depend on prior art and obviousness considerations, which remain central to patent litigation strategies.
FAQs
1. What is the primary legal issue in this case?
The case centers on whether Actavis’s generic formulation infringed Valeant’s patent and whether that patent is valid under U.S. patent law.
2. Why was the claim construction important?
Claim construction determined how patent terms were interpreted, directly influencing infringement and validity assessments.
3. Did the court find the patent valid and enforceable?
Yes, the court confirmed the patent’s validity and its infringement by Actavis.
4. What was the impact on market competition?
The ruling prevented Actavis from launching its generic drug until the patent expired or was invalidated, delaying competition.
5. How common are patent challenges in pharmaceutical litigation?
They are frequent, especially surrounding formulation patents with specific polymers and manufacturing processes, given their substantial market value.
References
[1] U.S. Patent No. 8,897,785. (2014). Assignee: Valeant Pharmaceuticals International, Inc.
[2] District Court D.N.J. Case No. 2:15-cv-08353. (2018). Judgment and opinion.
[3] Federal Circuit. (2018). Confirmation of patent validity and infringement decision.
